A Phase 3 interventional study of RSVPreF3 OA investigational vaccine and PCV20 in Respiratory Syncytial Virus Infections, sponsored by GlaxoSmithKline. Completed at 38 sites in 4 countries. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-18.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline — 1 open to participants now, 5 under way, 3 of them phase 3. Respiratory Syncytial Virus Infections · GlaxoSmithKline.
Among the 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline, this one is the 12th largest by enrollment, is one of 4 that started in 2023, is one of 21 in phase 3, and was the 29th registered.
306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.
Browse Respiratory Syncytial Virus Infections studies →1 of the 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline is open now, in 2 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States, Australia
Ages 18–80 · Healthy volunteers
By country, each count listing its studies:
Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.
This study: 60 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 13 · Phase 3 21
First in 2013; this study’s year is marked. 4 started in 2023.
This study's enrollment of 1,113 is above the median of 89 across 223 interventional studies indexed under Respiratory Syncytial Virus Infections.
Median enrollment 642 across the 40 interventional studies. Of the 33 that completed or were terminated, 30 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
1 of the studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07092865GlaxoSmithKlineA Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant | 2027-01-12 |
Add it to your calendar (.ics) → With an account.
Among the 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the ability of RSVPreF3 OA investigational vaccine to generate an immune response when given in combination with PCV20 and its safety in older adults, aged ≥60 years of age.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Planned or actual administration of a vaccine not foreseen by the study protocol in the period starting 30 days before the first study intervention administration and ending 30 days after the last study intervention administration. In the case of COVID 19 and inactivated/subunit influenza vaccines, this time window can be decreased to 14 days before and after each study intervention administration. In case of COVID-19 vaccine administration within 14 to 30 days window, the administration of COVID-19 vaccine should be in accordance with local government recommendations.
Note: In case an emergency mass vaccination for an unforeseen public health threat (e.g., a pandemic) is recommended and/or organized by the public health authorities outside the routine immunization program, the time period described above can be reduced if necessary for that vaccine, provided it is used according to the local governmental recommendations and that the Sponsor or designee is notified accordingly.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received both respiratory syncytial virus prefusion protein 3 older adult (RSVPreF3 OA) vaccine and 20-valent pneumococcal conjugate vaccine (PCV20) on Day 1.
Biological: RSVPreF3 OA investigational vaccine · Biological: PCV20
Participants received PCV20 vaccine on Day 1 and RSVPreF3 OA vaccine on Day 31.
Biological: RSVPreF3 OA investigational vaccine · Biological: PCV20
One dose of RSVPreF3 OA vaccine given intramuscularly in participant's non-dominant arm on Day 1 (in the Coad group) or Day 31(in the Control group).
Also known as: RSVPreF3 OA
One dose of the 20-valent pneumococcal conjugate vaccine (PCV20) given intramuscularly in participant's dominant arm (Coad group) or non-dominant arm (Control group) on Day 1
Also known as: 20 valent pneumococcal vaccine, Prevnar 20 (in US), Apexxnar (in Europe)
Adjusted Geometric Mean Titers (GMT) of Opsonophagocytic (OP) Titers at 1 Month After the PCV20 Vaccination
The OP titers were measured with multiplexed opsonophagocytosis assay and the results were expressed as GMT for each of the pneumococcal vaccine serotype.
Time frame: At Day 31
Adjusted GMTs of Respiratory Syncytial Virus-A (RSV-A) Neutralizing Titers [Estimated Dilution 60 (ED60)] at 1 Month After the RSVPreF3 OA Vaccination
Neutralizing titers were measured with neutralization assay and the results were expressed in ED60.
Time frame: At Day 31 for Co-administration Group and at Day 61 for Control Group
Adjusted GMTs of RSV-B Neutralizing Titers (ED60) at 1 Month After the RSVPreF3 OA Vaccination
Neutralizing titers were measured with neutralization assay and the results were expressed in ED60.
Time frame: At Day 31 for Co-administration Group and at Day 61 for Control Group
Mean Geometric Increase (MGI) of RSV-A Neutralizing Titers at 1 Month After the RSVPreF3 OA Vaccination
The MGI was defined as the geometric mean increase of the within participant ratios of the post-vaccination titer over the pre-vaccination titer. Neutralizing titers were measured with neutralization assay.
Time frame: At 1 month after the RSVPreF3 OA vaccine dose (Day 31 for Co-administration Group and Day 61 for Control Group) compared to Pre-vaccination (Day 1 for Co-administration Group and Day 31 for Control Group)
MGI of RSV-B Neutralizing Titers at 1 Month After the RSVPreF3 OA Vaccination
The MGI was defined as the geometric mean increase of the within participant ratios of the post-vaccination titer over the pre-vaccination titer. Neutralizing titers were measured with neutralization assay.
Time frame: At 1 month after the RSVPreF3 OA vaccine dose (Day 31 for Co-administration Group and Day 61 for Control Group) compared to Pre-vaccination (Day 1 for Co-administration Group and Day 31 for Control Group)
Number of Participants With Solicited Administration Site Adverse Events (AEs) After Each Vaccine Dose Administration
The solicited administration site events after vaccination include pain, erythema/redness, and swelling.
Time frame: Within 7 days (the day of vaccination and 6 subsequent days) after each vaccine administration (vaccines administered at Day 1 for Co-Administration Group and at Days 1 and 31 for Control group)
Number of Participants With Solicited Systemic AEs After Each Vaccine Dose Administration
The solicited systemic events after vaccination include fever (pyrexia), headache, fatigue, myalgia and arthralgia. Fever is defined as body temperature \>=38 degree Celsius; preferred location for measuring the temperature is oral.
Time frame: Within 7 days (the day of vaccination and 6 subsequent days) after each vaccine administration (vaccines administered at Day 1 for Co-Administration Group and at Days 1 and 31 for Control group)
Number of Participants With Unsolicited AEs
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the administration of a study vaccine, which does not necessarily have a causal relationship with study vaccine. An unsolicited AE is an AE that is either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events. Unsolicited AEs are communicated by participant/participant's caregiver(s) who have signed the informed consent. Unsolicited AEs include both serious adverse events (SAEs) and non-serious AEs.
Time frame: Within 30 days (the day of vaccination and 29 subsequent days) after each vaccine administration (vaccines administered at Day 1 for Co-Administration Group and at Days 1 and 31 for Control group)
Number of Participants With SAEs
An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.
Time frame: Throughout the study period (from Day 1 up to 6 months after the last dose administration [last dose given at Day 1 for Co-administration Group and Day 31 for Control Group])
Number of Participants With Potential Immune-mediated Diseases (pIMDs)
The pIMD is a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.
Time frame: Throughout the study period (from Day 1 up to 6 months after the last dose administration [last dose given at Day 1 for Co-administration Group and Day 31 for Control Group])
This study was conducted in adult participants aged 60 years and older, in 38 study sites.
| Milestone | Co-administration Group | Control Group |
|---|---|---|
| Started | 553 | 557 |
| Completed | 539 | 531 |
| Not completed | 14 | 26 |
| Withdrew: Withdrawal by participant, not due to an adverse event | 5 | 7 |
| Withdrew: Migrated / moved from the study area | 1 | 1 |
| Withdrew: Lost to follow-up | 8 | 13 |
| Withdrew: Death | 0 | 2 |
| Withdrew: Other | 0 | 3 |
The OP titers were measured with multiplexed opsonophagocytosis assay and the results were expressed as GMT for each of the pneumococcal vaccine serotype.
| Titers | Co-administration Group | Control Group |
|---|---|---|
| Strep pneumoniae - serotype 1 | 74.7 (64.1 to 87.1) | 110.8 (94.8 to 129.5) |
| Strep pneumoniae - serotype 3 | 88.5 (78.3 to 99.9) | 116.2 (102.7 to 131.5) |
| Strep pneumoniae - serotype 4 | 1220.9 (1072.9 to 1389.3) | 1634.1 (1433.4 to 1862.8) |
| Strep pneumoniae - serotype 5 | 191.0 (159.9 to 228.1) | 260.3 (217.3 to 311.8) |
| Strep pneumoniae - serotype 6A | 1790.0 (1527.8 to 2097.2) | 2458.3 (2091.8 to 2889.1) |
| Strep pneumoniae - serotype 6B | 2121.6 (1839.0 to 2447.6) | 2996.9 (2590.3 to 3467.2) |
| Strep pneumoniae - serotype 7F | 2411.3 (2154.1 to 2699.2) | 3225.1 (2876.2 to 3616.4) |
| Strep pneumoniae - serotype 8 | 522.9 (458.5 to 596.4) | 723.0 (632.5 to 826.5) |
| Strep pneumoniae - serotype 9V | 937.0 (822.3 to 1067.8) | 1161.0 (1016.7 to 1325.8) |
| Strep pneumoniae - serotype 10A | 6033.4 (5299.5 to 6868.9) | 7349.4 (6437.8 to 8389.9) |
| Strep pneumoniae - serotype 11A | 798.0 (691.5 to 921.0) | 944.2 (816.9 to 1091.5) |
| Strep pneumoniae - serotype 12F | 1608.4 (1382.9 to 1870.8) | 1932.4 (1656.5 to 2254.3) |
| Strep pneumoniae - serotype 14 | 2322.3 (2050.5 to 2630.1) | 3301.4 (2909.1 to 3746.7) |
| Strep pneumoniae - serotype 15B | 4336.4 (3765.8 to 4993.5) | 6350.2 (5500.4 to 7331.3) |
| Strep pneumoniae - serotype 18C | 1148.6 (997.6 to 1322.5) | 1480.0 (1282.4 to 1708.0) |
| Strep pneumoniae - serotype 19A | 1392.3 (1244.3 to 1557.8) | 1933.8 (1725.2 to 2167.7) |
| Strep pneumoniae - serotype 19F | 525.6 (461.6 to 598.5) | 696.7 (610.6 to 794.9) |
| Strep pneumoniae - serotype 22F | 5492.3 (4788.1 to 6300.1) | 7351.5 (6397.0 to 8448.5) |
| Strep pneumoniae - serotype 23F | 729.7 (613.0 to 868.6) | 995.0 (832.8 to 1188.7) |
| Strep pneumoniae - serotype 33F | 14902.8 (13220.7 to 16798.8) | 20920.9 (18526.9 to 23624.3) |
Neutralizing titers were measured with neutralization assay and the results were expressed in ED60.
| Titers | Co-administration Group | Control Group |
|---|---|---|
| Adjusted GMTs of Respiratory Syncytial Virus-A (RSV-A) Neutralizing Titers [Estimated Dilution 60 (ED60)] at 1 Month After the RSVPreF3 OA Vaccination | 8338.2 (7639.0 to 9101.4) | 8872.7 (8038.2 to 9793.9) |
Neutralizing titers were measured with neutralization assay and the results were expressed in ED60.
| Titers | Co-administration Group | Control Group |
|---|---|---|
| Adjusted GMTs of RSV-B Neutralizing Titers (ED60) at 1 Month After the RSVPreF3 OA Vaccination | 9477.5 (8695.4 to 10329.9) | 9497.6 (8620.5 to 10463.9) |
The MGI was defined as the geometric mean increase of the within participant ratios of the post-vaccination titer over the pre-vaccination titer. Neutralizing titers were measured with neutralization assay.
| Ratio | Co-administration Group | Control Group |
|---|---|---|
| Mean Geometric Increase (MGI) of RSV-A Neutralizing Titers at 1 Month After the RSVPreF3 OA Vaccination | 8.3 (7.6 to 9.1) | 9.3 (8.3 to 10.3) |
The MGI was defined as the geometric mean increase of the within participant ratios of the post-vaccination titer over the pre-vaccination titer. Neutralizing titers were measured with neutralization assay.
| Ratio | Co-administration Group | Control Group |
|---|---|---|
| MGI of RSV-B Neutralizing Titers at 1 Month After the RSVPreF3 OA Vaccination | 9.4 (8.6 to 10.2) | 9.1 (8.2 to 10.1) |
The solicited administration site events after vaccination include pain, erythema/redness, and swelling.
| Participants | Co-administration Group | Control Group |
|---|---|---|
| Pain at injection site, PCV20 dose, given at Day 1 | 283 | 208 |
| Pain at injection site, RSV dose, given at Day 1 | 290 | — |
| Pain at injection site, RSV dose, given at Day 31 | — | 225 |
| Erythema at injection site, PCV20 dose, given at Day 1 | 24 | 21 |
| Erythema at injection site, RSV dose, given at Day 1 | 54 | — |
| Erythema at injection site, RSV dose, given at Day 31 | — | 33 |
| Swelling at injection site, PCV20 dose, given at Day 1 | 17 | 17 |
| Swelling at injection site, RSV dose, given at Day 1 | 26 | — |
| Swelling at injection site, RSV dose, given at Day 31 | — | 21 |
The solicited systemic events after vaccination include fever (pyrexia), headache, fatigue, myalgia and arthralgia. Fever is defined as body temperature \>=38 degree Celsius; preferred location for measuring the temperature is oral.
| Participants | Co-administration Group | Control Group |
|---|---|---|
| Fever, Dosing at Day 1 | 16 | 4 |
| Fever, Dosing at Day 31 | — | 8 |
| Headache, Dosing at Day 1 | 144 | 83 |
| Headache, Dosing at Day 31 | — | 97 |
| Fatigue, Dosing at Day 1 | 198 | 152 |
| Fatigue, Dosing at Day 31 | — | 144 |
| Myalgia, Dosing at Day 1 | 176 | 89 |
| Myalgia, Dosing at Day 31 | — | 108 |
| Arthralgia, Dosing at Day 1 | 80 | 41 |
| Arthralgia, Dosing at Day 31 | — | 67 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the administration of a study vaccine, which does not necessarily have a causal relationship with study vaccine. An unsolicited AE is an AE that is either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events. Unsolicited AEs are communicated by participant/participant's caregiver(s) who have signed the informed consent. Unsolicited AEs include both serious adverse events (SAEs) and non-serious AEs.
| Participants | Co-administration Group | Control Group |
|---|---|---|
| Number of Participants With Unsolicited AEs | 60 | 98 |
An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.
| Participants | Co-administration Group | Control Group |
|---|---|---|
| Number of Participants With SAEs | 9 | 14 |
The pIMD is a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.
| Participants | Co-administration Group | Control Group |
|---|---|---|
| Number of Participants With Potential Immune-mediated Diseases (pIMDs) | 2 | 1 |
Collected over Solicited AEs were collected up to Day 7 post each vaccination. Unsolicited AEs were collected up to Day 30 post each vaccination. SAEs and pIMDs were collected throughout the study period from Day 1 up to 6 months post last vaccination.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Co-administration Group | 0/553 (0%) | 9/553 (1.6%) | 410/553 (74.1%) |
| Control Group | 2/557 (0.4%) | 14/557 (2.5%) | 423/557 (75.9%) |
| Event | Co-administration Group | Control Group |
|---|---|---|
| DeathGeneral disorders | 0/553 | 2/557 |
| PneumoniaInfections and infestations | 0/553 | 2/557 |
| Supraventricular tachycardiaCardiac disorders | 1/553 | 0/557 |
| Small intestinal obstructionGastrointestinal disorders | 1/553 | 0/557 |
| Pneumonia bacterialInfections and infestations | 1/553 | 0/557 |
| Fracture displacementInjury, poisoning and procedural complications | 1/553 | 0/557 |
| FallInjury, poisoning and procedural complications | 1/553 | 0/557 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/553 | 0/557 |
| Breast cancer stage INeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/553 | 0/557 |
| DizzinessNervous system disorders | 1/553 | 0/557 |
| Event | Co-administration Group | Control Group |
|---|---|---|
| Injection site painGeneral disorders | 337/553 | 312/557 |
| FatigueGeneral disorders | 198/553 | 217/557 |
| MyalgiaMusculoskeletal and connective tissue disorders | 176/553 | 157/557 |
| HeadacheNervous system disorders | 144/553 | 142/557 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 80/553 | 94/557 |
| Injection site erythemaGeneral disorders | 64/553 | 48/557 |
| Injection site swellingGeneral disorders | 38/553 | 38/557 |
| PyrexiaGeneral disorders | 18/553 | 13/557 |
| COVID-19Infections and infestations | 1/553 | 11/557 |
| Upper respiratory tract infectionInfections and infestations | 1/553 | 7/557 |
Exposed set included all participants in the Enrolled set who received at least 1 study intervention.
| Age, Continuous(years) | Co-administration Group | Control Group | Total |
|---|---|---|---|
| Mean | 69.6 ± 7.28 | 69.6 ± 7.41 | 69.6 ± 7.35 |
| Sex: Female, Male(Participants) | Co-administration Group | Control Group | Total |
|---|---|---|---|
| Female | 316 | 315 | 631 |
| Male | 237 | 242 | 479 |
| Race/Ethnicity, Customized(Participants) | Co-administration Group | Control Group | Total |
|---|---|---|---|
| Black or African American | 64 | 54 | 118 |
| All Other Races | 7 | 7 | 14 |
| White | 476 | 488 | 964 |
| Multiple | 2 | 4 | 6 |
| Other | 4 | 4 | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer tohttps://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk-studyregister.com
Ran from May 2023 to primary completion in Dec 2023, 6 months.
Results were first posted in May 2025, 1 year 5 months after primary completion. A results delay was requested in Dec 2024.
Of 27 industry-sponsored phase 3 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 19. This study's 6 months is below that.
Counting every sponsor, half of 32 studies reached it within 8 months; a quarter within 6 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pneumococcal 20-Valent Conjugate Vaccine
Respiratory Syncytial Virus Infections →